Esperion Therapeutics’ (ESPR) “Hold” Rating Reaffirmed at Chardan Capital

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “hold” rating reiterated by equities researchers at Chardan Capital in a research report issued to clients and investors on Thursday. They currently have a $50.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s price objective would indicate a potential upside of 1.98% from the stock’s previous close.

The analysts wrote, “We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:.””

Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. ValuEngine cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Northland Securities restated a “buy” rating and set a $65.00 target price on shares of Esperion Therapeutics in a research report on Friday, March 1st. BidaskClub upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Thursday, December 13th. They set a “sell” rating and a $45.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $73.08.

Shares of NASDAQ ESPR traded down $4.54 during midday trading on Thursday, hitting $49.03. The company had a trading volume of 1,121,309 shares, compared to its average volume of 425,763. Esperion Therapeutics has a twelve month low of $33.06 and a twelve month high of $79.81. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.50 and a beta of 2.17.

In related news, major shareholder Target N. V. Biotech bought 80,000 shares of the stock in a transaction that occurred on Friday, January 4th. The stock was purchased at an average cost of $41.29 per share, for a total transaction of $3,303,200.00. Following the completion of the acquisition, the insider now owns 3,472,964 shares in the company, valued at $143,398,683.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Target N. V. Biotech bought 50,000 shares of the stock in a transaction that occurred on Monday, December 24th. The stock was bought at an average price of $39.91 per share, with a total value of $1,995,500.00. Following the completion of the acquisition, the insider now owns 3,392,964 shares of the company’s stock, valued at approximately $135,413,193.24. The disclosure for this purchase can be found here. In the last three months, insiders bought 190,000 shares of company stock valued at $8,162,500. Company insiders own 14.50% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ESPR. Russell Investments Group Ltd. grew its holdings in Esperion Therapeutics by 598.3% in the third quarter. Russell Investments Group Ltd. now owns 12,422 shares of the biopharmaceutical company’s stock valued at $551,000 after purchasing an additional 10,643 shares during the period. American Century Companies Inc. grew its holdings in Esperion Therapeutics by 82.6% in the third quarter. American Century Companies Inc. now owns 52,544 shares of the biopharmaceutical company’s stock valued at $2,331,000 after purchasing an additional 23,769 shares during the period. JPMorgan Chase & Co. grew its holdings in Esperion Therapeutics by 3.4% in the third quarter. JPMorgan Chase & Co. now owns 71,095 shares of the biopharmaceutical company’s stock valued at $3,155,000 after purchasing an additional 2,348 shares during the period. Bank of New York Mellon Corp grew its holdings in Esperion Therapeutics by 5.6% in the third quarter. Bank of New York Mellon Corp now owns 117,796 shares of the biopharmaceutical company’s stock valued at $5,227,000 after purchasing an additional 6,212 shares during the period. Finally, Opera Trading Capital purchased a new stake in Esperion Therapeutics in the third quarter valued at approximately $173,000. Hedge funds and other institutional investors own 99.43% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: Why is the LIBOR significant?

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit